Biosimilars Market Size, Share, Growth and Forecast, 2025-2035

Biosimilars market size was valued at USD 31.01 billion in 2025 and is projected to reach USD 85.07 billion by 2035.

By Product (Monoclonal Antibodies, Insulins, Interferons, Erythropoiesis-Stimulating Agents, Anticoagulants, rhGH, GLP-1 Agonists, Others); By Indication (Autoimmune & Inflammatory, Oncology, Metabolic & Endocrine, Infectious Diseases, Other Applications); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies); By Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa)

SKU: CR22170Report Pages: 250Category: PharmaceuticalsReport Format: PDF, ExcelLast Updated: Nov 11Author: Shweta BishtReviewed by: Deepti AgrawalPreferred on

Market Report Metrics

Revenue, 2025 -
USD 31.01 billion
Forecast Year -
2035
CAGR (2025–2035)
10.62%
Report Coverage
Global

Biosimilars market grows as antibody exclusivity ends

The global biosimilars market was valued at USD 31.01 billion in 2025 and is projected to increase from USD 34.30 billion in 2026 to USD 85.07 billion by 2035, registering a CAGR of 10.62% during 2026–2035. Demand comes from health systems, insurers and hospitals that switch patients from high-cost reference biologics to lower-cost copies once exclusivity ends, mainly in immunology, oncology, diabetes, bone disease and eye care. Europe held the largest regional share, 36.0% in 2025, because national tenders and switching policies have supported uptake for many years. Asia Pacific is the fastest-growing region at 11.6% a year, as South Korea, India and China expand production and domestic access. The regulatory picture shifted in October 2025, when the U.S. Food and Drug Administration proposed that most biosimilars could skip comparative efficacy studies. As a result, development costs and timelines are set to fall for the next wave of products.

Which products and buyers does this analysis cover?

The analysis counts biologic medicines approved as biosimilar or interchangeable versions of a licensed reference product, including monoclonal antibodies, insulins, growth factors, hormones and other proteins, valued at manufacturer selling prices. Hospitals buy infused products through tenders and group contracts, while retail, specialty and online pharmacies dispense self-injected products such as insulins and adalimumab.

Reference biologics, small-molecule generics, unapproved copies and contract manufacturing fees sit outside the scope of this analysis. The value chain runs from developers and contract manufacturers through regulators, payers and pharmacy benefit managers to hospitals, pharmacies and patients.

Biosimilars Market Size, Share, Growth and Forecast, 2025-2035
Report Attribute Details
Details
Historical Period
2018–2025
Base Year
2025
Forecast Period
2025–2035
Biosimilars Size 2025
USD 31.01 billion
Biosimilars CAGR
10.62%
Biosimilars Size 2035
USD 85.07 billion

Biosimilars Market Insights

  • The biosimilars market grows from USD 31.01 billion in 2025 to USD 85.07 billion by 2035, a 10.62% CAGR driven by antibody patent expiries and payer savings programs.
  • Europe held 36.0% of global biosimilar value in 2025, supported by national tenders and long experience with switching.
  • Monoclonal antibodies led products with 58.0% of 2025 value, while GLP-1 agonists grow fastest among products at 14.7% a year.
  • In October 2025, the U.S. Food and Drug Administration issued draft guidance that would let most biosimilars rely on analytical data instead of comparative efficacy studies.
  • FDA listings show 18 biosimilar approvals in 2024 and another 18 in 2025, up from 5 in 2023, led by denosumab and ustekinumab copies.

Antibody copies lead as GLP-1 follow-ons gain pace

Why do antibody copies dominate product value?

Based on product, the market is categorized into monoclonal antibodies, insulins, interferons, erythropoiesis-stimulating agents, anticoagulants, rhGH, GLP-1 agonists and others. Monoclonal Antibodies led with a 58.0% share of 2025 value, because adalimumab, ustekinumab, denosumab and aflibercept copies replace some of the costliest antibody therapies in use. GLP-1 Agonists grow fastest at 14.7% a year, as follow-on peptide products reach more countries from a small base. Other products, mainly filgrastim and pegfilgrastim, remain a mature base.

Which therapy areas drive the most switching?

Based on indication, the market is categorized into oncology, autoimmune and inflammatory, infectious diseases, metabolic and endocrine and other applications. Autoimmune & Inflammatory conditions led with a 38.0% share of 2025 value, because adalimumab and ustekinumab copies serve patients who stay on therapy for years. Other Applications grow fastest at 11.4% a year, as eye care and bone disease copies of aflibercept and denosumab launch. Metabolic demand rests on insulin copies such as insulin glargine and insulin aspart.

Where do patients and hospitals obtain biosimilars?

Based on distribution channel, the market is categorized into hospital pharmacies, retail pharmacies and online pharmacies. Hospital Pharmacies led with a 52.0% share of 2025 value, because infused antibodies for cancer and immune disease are bought through hospital tenders. Online Pharmacies grow fastest at 12.4% a year, as self-injected copies and mail-order specialty fills gain ground. Retail pharmacies handle most insulin and adalimumab prescriptions for patients treated at home.

Segment GroupLeading Sub-segmentShare, 2025Fastest-growing Sub-segmentCAGR, 2026–2035
By ProductMonoclonal Antibodies58.0%GLP-1 Agonists14.7%
By IndicationAutoimmune & Inflammatory38.0%Other Applications11.4%
By Distribution ChannelHospital Pharmacies52.0%Online Pharmacies12.4%

Request a Free Sample

Fill in your details and we'll send you a free sample report.

  • Sample data tables & charts
  • Research methodology

Patent cliffs and payer savings targets lift uptake

How do expiring antibody patents open new markets?

Loss of exclusivity is the largest source of demand, because each expiring reference product opens a new pool of patients to lower-cost copies. According to the U.S. Department of Health and Human Services, biologics made up 5% of U.S. prescriptions but 51% of drug spending in 2024. This spending gap gives payers strong reasons to favor copies once biologic medicines lose protection. Sandoz, for example, launched an ustekinumab copy in the United States in February 2025, denosumab copies there in June 2025 and an aflibercept copy in Europe in November 2025. As a result, adalimumab, ustekinumab, denosumab and aflibercept copies lead new launches through 2027, with more antibody targets following later in the decade.

Why are FDA approvals accelerating?

Approval volumes are rising, because developers filed many applications for antibodies that lost exclusivity in 2023 to 2025. The FDA biosimilar product list shows 18 approvals in 2024 and 18 in 2025, compared with 5 in 2023 and 7 in 2022, and 8 more were listed from January to July 2026. Denosumab alone accounted for eight listings in 2025, while ustekinumab added 6 in 2024. Approvals also turn into launches quickly, because Celltrion sold five newer copies in 2025, including versions of ustekinumab, denosumab and aflibercept, soon after approval. In turn, more competitors per molecule push prices down and widen access for patients who previously could not afford treatment.

Heat map rating adalimumab, ustekinumab, denosumab, aflibercept and insulins on number of copies, price erosion, switching ease and remaining opportunity
Figure 1: Qualitative assessment of biosimilar molecules, 2025. Source: Credence Research assessment

Download Free Sample

How are regulators lowering development costs?

Modern analytics can now detect product differences better than large trials, and regulators are rewriting their rules to reflect this. In October 2025, the U.S. Food and Drug Administration issued draft guidance that would let most biosimilars rely on comparative analytical and pharmacokinetic data instead of efficacy studies, which the agency said can take 1 to three years and cost $24 million. In March 2026, the FDA proposed further changes that could save developers up to 50% of pharmacokinetic study costs, or about $20 million. In April 2025, the European Medicines Agency also opened consultation on a reflection paper on a tailored clinical approach. As a result, smaller developers can afford to target more molecules, which widens competition.

Why do payers and hospitals keep pushing switching?

Budget holders capture savings only when patients move to lower-cost copies, so payer and hospital policies keep volumes rising. European health systems use national and regional tenders that award most volume to 1 or two suppliers for each molecule, which steers large volumes to the lowest bidders. U.S. pharmacy benefit managers increasingly place biosimilars on preferred formulary tiers, sometimes under private labels. Sales at leading developers show this pull, because Sandoz reported that its biosimilar sales rose 13% at constant currency in 2025. In turn, uptake can move from low single digits to a majority of volume within a few years of first launch.

Lighter clinical rules and denosumab launches reshape supply

Is interchangeability becoming routine in the United States?

Interchangeability is becoming easier to obtain, because regulators no longer see switching studies as necessary for most products. With its October 2025 draft guidance, the U.S. Food and Drug Administration said it generally no longer recommends switching studies for interchangeable products. In March 2026, the agency followed with revised draft questions and answers for proposed biosimilar and interchangeable products, noting that it had approved 82 biosimilars to date, compared with 1 when its first such guidance appeared in April 2015. Interchangeable status lets pharmacists substitute a copy without a new prescription, subject to state laws. As a result, more self-injected products can compete directly at the pharmacy counter, which speeds uptake of insulin and adalimumab copies in retail channels, while online pharmacies grow fastest at 12.4% a year.

How is the denosumab wave reshaping bone health supply?

Denosumab copies are the largest new launch wave, because the reference products serve both osteoporosis and cancer-related bone complications. In September 2025, the FDA approved Biocon Biologics denosumab copies Bosaya and Aukelso, which joined several other approved versions. The FDA list shows 8 denosumab listings in 2025 alone, so competition per molecule is intense from the first year. Sandoz launched its denosumab pair, Wyost and Jubbonti, in the United States in June 2025 and in Europe in December 2025, which shows how quickly launches now cross the Atlantic. In turn, prices for bone health biologics are falling quickly, and other applications, which include bone disease, grow fastest by indication at 11.4% a year.

Timeline of biosimilar milestones from the April 2025 EMA consultation to the April 2026 FDA approval of Langlara
Figure 2: Approvals, guidance and portfolio milestones, 2025–2026. Source: FDA, EMA, Samsung Biologics, Coherus and Biocon releases

Download Free Sample

Where can contract manufacturers win new biosimilar work?

Contract manufacturing is a clear opening, because many developers prefer to outsource production rather than build plants. On Nov. 3, 2025, Samsung Biologics completed the spin-off of Samsung Bioepis, which separated its biosimilar business from its contract manufacturing operations. This structure lets the contract unit serve rival developers without conflict. The company also plans to finish a second Bio Campus by 2032, which would lift its total capacity to 1,324,000 liters. Developers that rent this capacity can then spend more of their budgets on analytics, filings and launches rather than on new plants. As a result, demand rises for contract biologics production in South Korea, India and Europe.

Can portfolio sales create value for focused players?

Portfolio deals are an opening for companies that want scale in a single therapy area, because mature products need efficient sales forces. In April 2025, Coherus BioSciences sold its UDENYCA franchise to Intas, whose Accord BioPharma unit took over the pegfilgrastim brand in the United States. The deal was valued at up to $558.4 million, including an upfront payment of $483.4 million and up to $75 million in sales milestones. The buyer gained an established oncology support product, while the seller shifted to novel cancer drugs. In turn, more mature copies are likely to move to specialist owners with lower costs.

Price erosion, patent thickets and rebates slow switching

Why does rapid price erosion squeeze margins?

Price erosion is the main commercial risk, because many developers launch copies of the same reference product at the same time. When 6 or more versions of one molecule reach the market, tenders and formularies reward the lowest bid. Developers that spent years on development may struggle to recover costs once prices fall. This pressure limits value growth even as patient volume rises, and it pushes weaker companies to sell or exit products.

How do patent thickets delay market entry?

Reference product owners hold many secondary patents on formulations, devices and manufacturing methods, and these thickets delay entry. Developers often must settle litigation and accept licensed entry dates years after the main patent expires. These delays are common in the United States, where biosimilar launches can trail European launches by several years. As a result, patients and payers wait longer for savings, and developers carry higher legal costs.

Do rebates and contracts slow switching?

Reference product owners can offer large rebates to keep formulary positions, which slows the move to copies. Pharmacy benefit managers may earn more from a high-list-price brand with rebates than from a low-price copy. This misalignment can slow uptake of self-injected copies in the United States even after several competitors launch. In turn, list price savings do not always reach patients, and uptake depends on how payers design formularies.

Why do physician and patient concerns persist?

Some prescribers and patients worry about switching a stable patient to a new product, which still limits uptake in some areas. Device differences, such as autoinjector design, can also lead patients to resist a change. HHS noted in October 2025 that biosimilars held below 20% of the relevant U.S. market. As a result, education programs and patient support services remain important for developers that want to grow share.

Europe leads on tenders as Asia Pacific builds capacity

RegionValue, 2025 (USD billion)Share, 2025CAGR, 2026–2035
Europe11.1636.0%9.6%
North America10.2333.0%10.9%
Asia Pacific6.5121.0%11.6%
Latin America1.866.0%11.0%
Middle East & Africa1.244.0%11.1%

Why does Europe hold the largest regional share?

Europe held a 36.0% share of 2025 value and grows at 9.6% a year through 2035. The region approved biosimilars earlier than other markets, and national tenders in countries such as Norway, Denmark, Germany and the United Kingdom award large volumes to winning bidders. In April 2025, the European Medicines Agency opened consultation on lighter clinical requirements, which could lower development costs further. However, deep price cuts in mature tenders keep regional value growth below the global rate.

How fast is North America catching up?

North America held a 33.0% share of 2025 value and grows at 10.9% a year through 2035. The United States is adding copies of adalimumab, ustekinumab, denosumab and aflibercept, and FDA listings show 18 approvals in both 2024 and 2025. Draft guidance issued in October 2025 could shorten development further. However, rebate contracts and patent settlements still slow uptake compared with Europe, so growth depends on payer formulary choices.

Lollipop chart of FDA biosimilar approval listings showing 4 in 2021, 7 in 2022, 5 in 2023, 18 in 2024 and 18 in 2025
Figure 3: FDA biosimilar approval listings, 2021–2025. Source: US FDA Biosimilar Product Information

Download Free Sample

Why is Asia Pacific the fastest-growing region?

Asia Pacific held a 21.0% share of 2025 value and is the fastest-growing region at 11.6% a year. South Korea hosts major developers and contract manufacturers, while India and China have large domestic producers such as Biocon and Bio-Thera Solutions. Governments use copies to widen access to cancer and immune therapies that were previously unaffordable. As a result, both domestic demand and export production expand faster than in Western markets.

Where is Latin America adding demand?

Latin America held a 6.0% share of 2025 value and grows at 11.0% a year through 2035. Brazil and Mexico lead regional demand, where public health systems buy copies of oncology and immune antibodies through tenders. Local production partnerships help governments secure supply at lower prices.

What limits growth in the Middle East and Africa?

The Middle East and Africa held a 4.0% share of 2025 value and grows at 11.1% a year through 2035. Gulf states buy copies through centralized procurement, while access across much of Africa remains limited by budgets and cold chain capacity.

Donut chart of 2025 regional shares with Europe 36.0%, North America 33.0%, Asia Pacific 21.0%, Latin America 6.0% and Middle East and Africa 4.0%
Figure 4: Regional share of 2025 biosimilars value. Source: Credence Research estimates

Download Free Sample

Approvals, guidance and portfolio moves since 2025

DevelopmentStatus and market relevance
In April 2025, Coherus BioSciences completed the sale of its UDENYCA pegfilgrastim franchise to Intas, whose Accord BioPharma unit took over U.S. sales.Completed; moves a mature oncology support product to a specialist owner
In September 2025, the FDA approved Biocon Biologics denosumab copies Bosaya and Aukelso for all indications of Prolia and Xgeva.Approved; adds to a crowded denosumab field in the United States
In October 2025, the FDA issued draft guidance that would let most biosimilars rely on analytical data instead of comparative efficacy studies.Draft guidance; lowers expected development cost and time
In November 2025, Samsung Biologics completed a spin-off that created Samsung Epis Holdings, parent of its biosimilar business.Completed; separates biosimilar development from contract manufacturing
In April 2026, the FDA approved Langlara, an insulin glargine biosimilar to Lantus.Approved; widens long-acting insulin competition

Analytics, interchangeability and devices shape products

  • Advanced analytical characterization such as high-resolution mass spectrometry lets developers show similarity with fewer clinical studies, which supports the lighter rules proposed in 2025.
  • Interchangeable designations allow pharmacy-level substitution in the United States, which makes self-injected copies easier to dispense in retail channels.
  • Patient-friendly devices including autoinjectors and high-concentration, citrate-free formulations reduce injection pain, which helps patients accept a switch.
  • High-titer continuous manufacturing raises output per plant, which lowers the cost of goods for copies that compete in tight tenders.

Need a Custom Version of This Report?

Tailor the scope, geography, or segments to your exact requirements.

  • Custom geography or segment scope
  • Direct access to our analyst team

Developers compete on cost, capacity and first entry

Competition splits between large global developers, Asian producers with low-cost manufacturing and specialists that buy mature products. Amgen and Pfizer market copies of antibodies, growth factors and other proteins across major markets. Sandoz, spun off from Novartis in 2023, competes as a focused generics and biosimilars company with a broad antibody portfolio. Teva Pharmaceutical Industries and STADA Arzneimittel compete through partnerships and strong pharmacy sales networks, while Dr. Reddy's builds a biosimilar pipeline for emerging and regulated markets. Celltrion, Samsung Bioepis, Biocon and Bio-Thera Solutions represent Asian development and production scale, while Alvotech develops copies that partners such as Teva and STADA sell. The 11 companies profiled below span global developers, regional producers and partners. However, tender pricing limits pricing power for every company once several copies of a molecule are available.

Companies profiled and their roles in this market

CompanyTypeRole in the market
SandozGlobal biosimilar specialistAdalimumab, denosumab, ustekinumab and aflibercept copies across major markets
AmgenGlobal developerBiosimilar antibodies alongside its own reference biologics
PfizerGlobal developerOncology and immunology biosimilars across major markets
CelltrionDeveloper and manufacturerInfliximab, rituximab and trastuzumab copies plus newer ustekinumab and denosumab copies
Samsung Bioepis (Samsung Epis Holdings)DeveloperAdalimumab, ustekinumab, aflibercept and denosumab copies, often sold through partners
Teva Pharmaceutical Industries Ltd.Commercial partnerPartnered biosimilars with U.S. retail and specialty reach
BioconDeveloper and manufacturerInsulins, oncology antibodies and denosumab copies
AlvotechDeveloper and manufacturerAdalimumab and ustekinumab copies sold through partners such as Teva and STADA
STADA Arzneimittel AGCommercial partnerEuropean marketing of partnered biosimilars
Dr. Reddy'sDeveloperBiosimilar pipeline for emerging and regulated markets
Bio Thera SolutionsDeveloper and manufacturerChinese developer of Avzivi, a bevacizumab copy approved by the FDA

Volume rises faster than value as more copies arrive

Credence Research's view is that biosimilar volumes will grow much faster than value through 2035, because each new molecule attracts several competitors within a year of launch. The overall market still grows at 10.62% a year, supported by antibody patent expiries, lighter development rules and payer savings targets. The best opportunities sit with developers that reach the market first or hold the lowest production costs. Companies that combine strong analytics, low-cost plants and patient support will hold share as tenders tighten.

How Credence Research sized follow-on biologic spending

The report uses 2025 as the base year and 2026 to 2035 as the forecast period. Market values come from the Credence Research model, which builds spending by product, indication and distribution channel. Regional and segment splits are Credence Research estimates informed by FDA approval listings, European Medicines Agency documents, U.S. Department of Health and Human Services releases and company press releases. No primary interviews or surveys were used in preparing this edition of the report.

Follow-on biologic spending outlook to 2035

By 2035, the biosimilars market is projected to reach USD 85.07 billion, with growth led by antibody copies and by faster uptake in Asia Pacific and North America. Denosumab, ustekinumab and aflibercept copies will mature, while new targets such as pertuzumab, golimumab and omalizumab add later waves. Lighter clinical rules could bring more developers into each molecule, which raises volume but cuts price. Europe keeps a large share through tenders, while the United States grows as rebate barriers ease. As a result, advantage will depend on cost, timing and device quality.

Frequently Asked Questions

How big is the global biosimilars market?
The global biosimilars market was valued at USD 31.01 billion in 2025 and is projected to reach USD 85.07 billion by 2035. It is expected to grow at a 10.62% CAGR during 2026–2035, supported by antibody patent expiries and payer savings targets.
Which product type leads the biosimilars market?
Monoclonal antibodies led with 58.0% of 2025 value, because adalimumab, ustekinumab, denosumab and aflibercept copies replace costly reference products. GLP-1 agonists grow fastest at 14.7% a year from a small base.
Which region leads biosimilar spending?
Europe led with 36.0% of 2025 value, supported by national tenders and long switching experience. Asia Pacific is the fastest-growing region at 11.6% a year as South Korea, India and China expand supply.
How many biosimilars has the FDA approved recently?
FDA listings show 18 biosimilar approvals in 2024 and 18 in 2025, compared with 5 in 2023. Denosumab and ustekinumab copies made up a large part of these recent approvals in the United States.
How will the 2025 FDA draft guidance affect biosimilars?
The October 2025 draft guidance would let most biosimilars rely on analytical and pharmacokinetic data instead of comparative efficacy studies. This change could lower development costs and bring more developers into each molecule.
Which indication accounts for the most biosimilar spending?
Autoimmune and inflammatory conditions led with 38.0% of 2025 value, because adalimumab and ustekinumab copies serve long-term patients. Other applications such as eye care and bone disease grow fastest at 11.4% a year.
Who are the leading biosimilar companies?
Key companies include Sandoz, Amgen, Pfizer, Celltrion, Samsung Bioepis, Teva Pharmaceutical Industries, Biocon, Alvotech, STADA Arzneimittel, Dr. Reddy's and Bio-Thera Solutions, and Sandoz was spun off from Novartis in October 2023.
What restrains growth in biosimilars?
Rapid price erosion, patent thickets, rebate contracts and switching concerns restrain growth. HHS noted in October 2025 that biosimilars held below 20% of the relevant U.S. market despite many approvals.

Table of Content

Chapter 1 Market Segmentation

  • 1.1 Segmentation Framework
    • 1.1.1 Product and Service Classification
    • 1.1.2 Application and End-Use Classification
    • 1.1.3 Technology and Solution Classification
    • 1.1.4 Customer and Distribution Channel Classification
    • 1.1.5 Geographic Segmentation
    • 1.1.6 Market Segment Definitions and Boundaries
  • 1.2 By Product
    • 1.2.1 Monoclonal Antibodies
    • 1.2.2 Insulins
    • 1.2.3 Interferons
    • 1.2.4 Erythropoiesis-Stimulating Agents
    • 1.2.5 Anticoagulants
    • 1.2.6 rhGH
    • 1.2.7 GLP-1 Agonists
    • 1.2.8 Others
  • 1.3 By Indication
    • 1.3.1 Autoimmune & Inflammatory
    • 1.3.2 Oncology
    • 1.3.3 Metabolic & Endocrine
    • 1.3.4 Infectious Diseases
    • 1.3.5 Other Applications

Chapter 2 Introduction

  • 2.1 Report Objectives and Scope
  • 2.2 Product Definition and Industry Terminology
  • 2.3 Market Inclusions and Exclusions
  • 2.4 Research Process
    • 2.4.1 Primary Research and Expert Interviews
    • 2.4.2 Secondary Research and Source Review
    • 2.4.3 Top-Down and Bottom-Up Estimation
    • 2.4.4 Data Triangulation and Verification
  • 2.5 Market Size Measurement Basis
    • 2.5.1 2025: USD 31.01 billion → 2035: USD 85.07 billion
  • 2.6 Historical and Forecast Reference Periods
    • 2.6.1 Historical Period: 2018-2025
    • 2.6.2 Base Year: 2025
    • 2.6.3 Forecast Period: 2025-2035
  • 2.7 Research Assumptions and Limitations

Chapter 3 Executive Summary

  • 3.1 Market Snapshot and Key Findings
  • 3.2 Base-Year Market Size, 2025
  • 3.3 Forecast Market Size, 2035
  • 3.4 Revenue and Volume Growth Outlook
  • 3.5 Key Demand and Supply Indicators
  • 3.6 Leading Market Segments
  • 3.7 Fastest-Growing Market Opportunities
  • 3.8 Regional Performance Highlights
  • 3.9 Technology and Industry Transformation
  • 3.10 Competitive Landscape Summary
  • 3.11 Analyst View and Strategic Implications

Chapter 4 Global Biosimilars Market Trends and Developments

  • 4.1 Historical Industry Development, 2018-2025
  • 4.2 Recent Market Trends and Developments
  • 4.3 Demand and Customer Behavior Trends
  • 4.4 Technology and Product Innovation
  • 4.5 Artificial Intelligence, Automation and Digitalization
  • 4.6 Local Manufacturing and Supply Chain Realignment
  • 4.7 Industry Partnerships, Mergers and Acquisitions
  • 4.8 Sustainability and Circular Economy Developments
  • 4.9 Government and Private Sector Investment Trends
  • 4.10 Emerging Business Models and Commercialization
  • 4.11 Industry Developments and Announcements

Chapter 5 Global Biosimilars Market Production, Supply and Demand Analysis

  • 5.1 Demand Trend and Consumption Analysis, 2018-2025
  • 5.2 Demand Forecast, 2025-2035
  • 5.3 Production and Output Trend, 2018-2025
  • 5.4 Production and Output Forecast, 2025-2035
  • 5.5 Installed Capacity and Capacity Utilization
  • 5.6 Company-Wise Production Plants and Statistics
    • 5.6.1 Installed Production Capacity
    • 5.6.2 Actual Production
    • 5.6.3 Planned Capacity and Expansion Targets
  • 5.7 Supply Chain Structure and Procurement Trends
  • 5.8 Supply-Demand Gap and Bottlenecks
  • 5.9 Import Dependence and Sourcing Structure
  • 5.10 Contract Manufacturing and Outsourcing
  • 5.11 Regional Supply and Demand Concentration

Chapter 6 Global Biosimilars Market Pricing Analysis

  • 6.1 Pricing Structure and Measurement
  • 6.2 Historical Pricing Trends, 2018-2025
  • 6.3 Pricing Outlook, 2025-2035
  • 6.4 Average Selling Price and Unit Economics
  • 6.5 Pricing by Product and Market Segment
  • 6.6 Geographic Pricing Differences
  • 6.7 Key Input, Energy, Labor and Logistics Costs
  • 6.8 Contract Pricing and Purchasing Models
  • 6.9 Pricing Sensitivity and Competitive Positioning
  • 6.10 Price, Margin and Profitability Implications

Chapter 7 Global Biosimilars Market Dynamics

  • 7.1 Market Growth Drivers
    • 7.1.1 Demand-Side Drivers
    • 7.1.2 Technology and Innovation Drivers
    • 7.1.3 Infrastructure and Investment Drivers
    • 7.1.4 Regulatory and Policy Drivers
  • 7.2 Market Restraints
    • 7.2.1 Cost and Affordability Constraints
    • 7.2.2 Technology and Adoption Barriers
    • 7.2.3 Supply Chain and Operational Constraints
  • 7.3 Market Challenges
    • 7.3.1 Competitive Pressure and Margin Erosion
    • 7.3.2 Skills, Infrastructure and Implementation Gaps
  • 7.4 Emerging Market Opportunities
  • 7.5 Market Dynamics Impact and Time-Horizon Assessment

Chapter 8 Global Biosimilars Value Chain Analysis

  • 8.1 Industry Value Chain Overview
  • 8.2 Upstream Suppliers and Critical Inputs
  • 8.3 Technology and Component Providers
  • 8.4 Manufacturing or Service Delivery
  • 8.5 Distribution, Channel Partners and Integrators
  • 8.6 Downstream Applications and End Users
  • 8.7 Value Addition and Profit Pools
  • 8.8 Vertical Integration and Outsourcing
  • 8.9 Supplier Concentration and Risk
  • 8.10 Supply Chain Localization and Resilience

Chapter 9 Global Biosimilars Market Regulations and Policies

  • 9.1 Relevant Laws, Standards and Compliance Frameworks
  • 9.2 Product, Service, Safety and Quality Requirements
  • 9.3 Government Policies, Incentives and Subsidies
  • 9.4 Imports, Exports and Trade Barriers
  • 9.5 Public Procurement and Local Content Requirements
  • 9.6 Environmental and Sustainability Compliance
  • 9.7 Upcoming Policy Changes and Market Implications

Chapter 10 Global Biosimilars Market Hotspots and Opportunities

  • 10.1 Market Opportunity Mapping and Growth Hotspots
  • 10.2 High-Growth Applications and Customer Groups
  • 10.3 Underserved Markets and White-Space Opportunities
  • 10.4 Emerging Technology and Product Opportunities
  • 10.5 New Capacity and Investment Hotspots
  • 10.6 Market Entry and Expansion Opportunities
  • 10.7 Distribution and Partnership Opportunities
  • 10.8 Near-Term and Long-Term Commercial Potential
  • 10.9 Opportunity Attractiveness and Execution Risks

Chapter 11 Global Biosimilars Market Outlook, 2025-2035

  • 11.1 Market Size and Analysis
    • 11.1.1 Revenue (Market Measurement: 2025: USD 31.01 billion → 2035: USD 85.07 billion)
    • 11.1.2 Market Volume and Quantity Sold
    • 11.1.3 Historical Market Size, 2018-2025
    • 11.1.4 Base-Year Market Size, 2025
  • 11.2 Market Forecast, 2025-2035
    • 11.2.1 Revenue Forecast to 2035
    • 11.2.2 Volume Forecast to 2035
    • 11.2.3 CAGR and Year-on-Year Growth
    • 11.2.4 Incremental Revenue Opportunity
  • 11.3 Forecast Assumptions and Scenario Analysis
    • 11.3.1 Base-Case Forecast
    • 11.3.2 Optimistic and Conservative Scenarios
    • 11.3.3 Technology, Pricing and Policy Sensitivities
  • 11.4 Market Attractiveness and Growth Outlook

Chapter 12 Global Biosimilars Market Segmentation and Outlook

  • 12.1 Segmentation Summary and Market Shares, 2025
  • 12.2 Largest and Fastest-Growing Segments
  • 12.3 By Product - Market Size and Forecast, 2025-2035
    • 12.3.1 Segment Definition and Scope
    • 12.3.2 Historical Market Size, 2018-2025
    • 12.3.3 Revenue Forecast, 2025-2035
    • 12.3.4 Volume Forecast, 2025-2035
    • 12.3.5 Base-Year Market Share, 2025
    • 12.3.6 Segment CAGR and Growth Drivers
    • 12.3.7 Subsegment Market Size and Forecast
      • 12.3.7.1 Monoclonal Antibodies
      • 12.3.7.2 Insulins
      • 12.3.7.3 Interferons
      • 12.3.7.4 Erythropoiesis-Stimulating Agents
      • 12.3.7.5 Anticoagulants
      • 12.3.7.6 rhGH
      • 12.3.7.7 GLP-1 Agonists
      • 12.3.7.8 Others
    • 12.3.8 Subsegment Pricing and Adoption Trends
    • 12.3.9 Leading Suppliers and Competition
    • 12.3.10 Regional Demand and Opportunities
  • 12.4 By Indication - Market Size and Forecast, 2025-2035
    • 12.4.1 Segment Definition and Scope
    • 12.4.2 Historical Market Size, 2018-2025
    • 12.4.3 Revenue Forecast, 2025-2035
    • 12.4.4 Volume Forecast, 2025-2035
    • 12.4.5 Base-Year Market Share, 2025
    • 12.4.6 Segment CAGR and Growth Drivers
    • 12.4.7 Subsegment Market Size and Forecast
      • 12.4.7.1 Autoimmune & Inflammatory
      • 12.4.7.2 Oncology
      • 12.4.7.3 Metabolic & Endocrine
      • 12.4.7.4 Infectious Diseases
      • 12.4.7.5 Other Applications
    • 12.4.8 Subsegment Pricing and Adoption Trends
    • 12.4.9 Leading Suppliers and Competition
    • 12.4.10 Regional Demand and Opportunities
  • 12.5 Segment Growth Comparison
  • 12.6 Segment Attractiveness and Priority Matrix

Chapter 13 Global Biosimilars Geographic Market Outlook, 2025-2035

  • 13.1 Regional Market Size and Share, 2025
  • 13.2 Regional Market Forecast, 2025-2035
  • 13.3 Regional Pricing, Production and Demand Differences
  • 13.4 North America
    • 13.4.1 United States
    • 13.4.2 Canada
    • 13.4.3 Mexico
  • 13.5 Europe
    • 13.5.1 Germany
    • 13.5.2 France
    • 13.5.3 Italy
    • 13.5.4 United Kingdom
    • 13.5.5 Spain
    • 13.5.6 Poland
    • 13.5.7 Russia
    • 13.5.8 Netherlands
    • 13.5.9 Belgium
    • 13.5.10 Sweden
    • 13.5.11 Denmark
    • 13.5.12 Norway
    • 13.5.13 Rest of Europe
  • 13.6 Asia Pacific
    • 13.6.1 China
    • 13.6.2 India
    • 13.6.3 Japan
    • 13.6.4 South Korea
    • 13.6.5 Thailand
    • 13.6.6 Indonesia
    • 13.6.7 Vietnam
    • 13.6.8 Malaysia
    • 13.6.9 Australia
    • 13.6.10 Rest of Asia Pacific
  • 13.7 Latin America
    • 13.7.1 Brazil
    • 13.7.2 Argentina
    • 13.7.3 Colombia
    • 13.7.4 Chile
    • 13.7.5 Rest of Latin America
  • 13.8 Middle East
    • 13.8.1 Saudi Arabia
    • 13.8.2 United Arab Emirates
    • 13.8.3 Turkey
    • 13.8.4 Israel
    • 13.8.5 Iran
    • 13.8.6 Rest of the Middle East
  • 13.9 Africa
    • 13.9.1 South Africa
    • 13.9.2 Egypt
    • 13.9.3 Nigeria
    • 13.9.4 Morocco
    • 13.9.5 Rest of Africa
  • 13.10 Regional Investment, Policy and Supply Chain Differences
  • 13.11 Regional Competitive Landscape
  • 13.12 Geographic Growth Hotspots

Chapter 14 Global Biosimilars Technology, Innovation and Sustainability Outlook

  • 14.1 Technology Landscape and Maturity
  • 14.2 Product, Process and Service Innovation
  • 14.3 AI, Automation and Digital Tools in the Industry
  • 14.4 Technology Adoption and Performance Benchmarking
  • 14.5 Innovation Pipeline and R&D Investment
  • 14.6 Patent and Intellectual Property Trends
  • 14.7 Energy Efficiency and Resource Management
  • 14.8 Sustainability, Recycling and Circularity
  • 14.9 Technology Roadmap, 2025-2035
  • 14.10 Risks of Obsolescence and Technology Substitution

Chapter 15 Global Biosimilars Market Key Strategic Imperatives

  • 15.1 Growth and Market Entry Priorities
  • 15.2 High-Return Products and Segments
  • 15.3 Pricing, Profitability and Cost Optimization
  • 15.4 Technology Investment and Product Differentiation
  • 15.5 Supply Chain Localization and Resilience
  • 15.6 Distribution and Customer Acquisition
  • 15.7 Partnership, Acquisition and Capacity Strategy
  • 15.8 Regional Expansion Priorities
  • 15.9 Short-, Medium- and Long-Term Actions

Chapter 16 Competition Outlook

  • 16.1 Industry Competition Characteristics
  • 16.2 Market Structure and Concentration
  • 16.3 Market Share and Competitive Positioning, 2025
  • 16.4 Company-Wise Revenue and Product Benchmarking
  • 16.5 Production and Service Capacity Benchmarking
  • 16.6 Technology, Pricing and Differentiation
  • 16.7 Regional Footprint and Distribution Strength
  • 16.8 Mergers, Acquisitions and Strategic Alliances
  • 16.9 New Entrants and Competitive Threats
  • 16.10 Porter's Five Forces and Industry Attractiveness
  • 16.11 Competitive Outlook, 2025-2035

Chapter 17 Company Profiles

  • 17.1 Company Coverage and Selection Criteria
  • 17.2 Sandoz
    • 17.2.1 Business Description
    • 17.2.2 Company Ownership and Geographic Presence
    • 17.2.3 Product and Service Portfolio
    • 17.2.4 Manufacturing and Operating Footprint
    • 17.2.5 Production Capacity and Expansion Plans
    • 17.2.6 Financial Performance and Investment
    • 17.2.7 Market Share and Competitive Position
    • 17.2.8 Technology and Innovation Capabilities
    • 17.2.9 Strategic Alliances or Partnerships
    • 17.2.10 Recent Developments
    • 17.2.11 Growth Strategy and Outlook
  • 17.3 Amgen
  • 17.4 Pfizer
  • 17.5 Celltrion
  • 17.6 Samsung Bioepis (Samsung Epis Holdings)
  • 17.7 Teva Pharmaceutical Industries Ltd.
  • 17.8 Biocon
  • 17.9 Alvotech
  • 17.10 STADA Arzneimittel AG
  • 17.11 Dr. Reddy's
  • 17.12 Bio Thera Solutions
  • 17.13 Other Relevant Market Participants

Note: Every listed company is profiled on the structure shown under the first company. The company list is preliminary and may change based on research findings, market developments, data availability and client requirements.

Chapter 18 Disclaimer

  • 18.1 Research and Forecast Disclaimer
  • 18.2 Data Source and Estimation Limitations

Note: The depth of individual sections depends on data availability for this market. Volume, capacity, trade and other unit-based metrics are included where applicable.

Methodology

Meet the Team

Shweta Bisht
Shweta Bisht

Healthcare & Biotech Analyst

Shweta is a healthcare and biotech researcher with strong analytical skills in chemical and agri domains.

Deepti Agrawal

Reviewed by

Deepti Agrawal

Head of Editorial Operations

Related Topics

North America Retail Pharmacy Market Size, Share, Growth and Forecast, 2025-2035

North America retail pharmacy market worth USD 562.72 billion in 2025 is set to reach USD 821.03 billion by 2035 at a 3.85% CAGR as prescriptions rise

Radiopharmaceutical Theranostics Market Size, Share, Growth and Forecast, 2025-2035

Radiopharmaceutical theranostics market grows from USD 5.58 billion in 2025 to USD 17.18 billion by 2035 at an 11.90% CAGR as PSMA therapy moves earlier.

Japan Retail Pharmacy Market Size, Share, Growth and Forecast, 2025-2035

Japan retail pharmacy market worth USD 64.85 billion in 2025 is forecast to reach USD 90.60 billion by 2035 at a 3.40% CAGR as aging lifts dispensing.

Europe Electronic Medical Record (EMR) Market Size, Share, Growth and Forecast, 2025-2035

Europe electronic medical record (EMR) market worth USD 10.25 billion in 2025 will reach USD 18.01 billion by 2035 at a 5.80% CAGR as EHDS rules drive upgrades.

Asia Pacific Drug Development Market Size, Share, Growth and Forecast, 2025-2035

Asia Pacific drug development market worth USD 50.29 billion in 2025 reaches USD 95.38 billion by 2035 at a 6.58% CAGR as biologics pipelines grow.

India Gene Therapy Market Size, Share, Growth and Forecast, 2025-2035

India gene therapy market worth USD 63.5 million in 2025 is set to reach USD 1.12 billion by 2035 at a 32.19% CAGR as domestic CAR-T scales.